Reinforcement learning informs optimal treatment strategies to limit antibiotic resistance.

antibiotic resistance artificial intelligence evolution

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
16 Apr 2024
Historique:
medline: 12 4 2024
pubmed: 12 4 2024
entrez: 12 4 2024
Statut: ppublish

Résumé

Antimicrobial resistance was estimated to be associated with 4.95 million deaths worldwide in 2019. It is possible to frame the antimicrobial resistance problem as a feedback-control problem. If we could optimize this feedback-control problem and translate our findings to the clinic, we could slow, prevent, or reverse the development of high-level drug resistance. Prior work on this topic has relied on systems where the exact dynamics and parameters were known a priori. In this study, we extend this work using a reinforcement learning (RL) approach capable of learning effective drug cycling policies in a system defined by empirically measured fitness landscapes. Crucially, we show that it is possible to learn effective drug cycling policies despite the problems of noisy, limited, or delayed measurement. Given access to a panel of 15 [Formula: see text]-lactam antibiotics with which to treat the simulated

Identifiants

pubmed: 38607932
doi: 10.1073/pnas.2303165121
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2303165121

Subventions

Organisme : HHS | National Institutes of Health (NIH)
ID : 5R37CA244613-03
Organisme : HHS | National Institutes of Health (NIH)
ID : 5T32GM007250-46
Organisme : HHS | National Institutes of Health (NIH)
ID : T32CA094186

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Davis T Weaver (DT)

Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH 44106.

Eshan S King (ES)

Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH 44106.

Jeff Maltas (J)

Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH 44106.

Jacob G Scott (JG)

Case Western Reserve University School of Medicine, Cleveland, OH 44106.
Translational Hematology Oncology Research, Cleveland Clinic, Cleveland, OH 44106.
Department of Physics, Case Western Reserve University, Cleveland, OH 44106.

Classifications MeSH